According to the court, “some patients did better on a lower dose and others experienced the same lack of clinical benefit whether they were on the higher dose or not,” and therefore, the defendants failed to disclose the subgroup data, “which would have contextualized their ‘all data’ claim,” leading the complaint to plausibly allege that the defendants omission mislead investors.